Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of 2.78 billion. The enterprise value is 4.75 billion.

Market Cap	2.78B
Enterprise Value	4.75B

Important Dates

The next estimated earnings date is Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	397.29M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	180.16M

Valuation Ratios

The trailing PE ratio is 17.61.

PE Ratio	17.61
Forward PE	n/a
PS Ratio	1.04
PB Ratio	2.46
P/TBV Ratio	n/a
P/FCF Ratio	52.01
P/OCF Ratio	25.22
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.61, with an EV/FCF ratio of 88.94.

EV / Earnings	30.11
EV / Sales	1.76
EV / EBITDA	18.61
EV / EBIT	57.86
EV / FCF	88.94

Financial Position

The company has a current ratio of 1.07, with a Debt / Equity ratio of 1.85.

Current Ratio	1.07
Quick Ratio	0.43
Debt / Equity	1.85
Debt / EBITDA	8.14
Debt / FCF	39.27
Interest Coverage	2.09

Financial Efficiency

Return on equity (ROE) is 14.52% and return on invested capital (ROIC) is 1.52%.

Return on Equity (ROE)	14.52%
Return on Assets (ROA)	0.99%
Return on Invested Capital (ROIC)	1.52%
Return on Capital Employed (ROCE)	2.58%
Revenue Per Employee	695,030
Profits Per Employee	41,186
Employee Count	3,832
Asset Turnover	0.48
Inventory Turnover	1.46

Taxes

Income Tax	-40.23M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +218.59% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+218.59%
50-Day Moving Average	3.93
200-Day Moving Average	10.65
Relative Strength Index (RSI)	66.03
Average Volume (20 Days)	423

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of 2.66 billion and earned 157.83 million in profits. Earnings per share was 0.40.

Revenue	2.66B
Gross Profit	1.64B
Operating Income	86.97M
Pretax Income	117.60M
Net Income	157.83M
EBITDA	257.67M
EBIT	86.97M
Earnings Per Share (EPS)	0.40

Full Income Statement

Balance Sheet

The company has 154.37 million in cash and 2.10 billion in debt, giving a net cash position of -1.94 billion.

Cash & Cash Equivalents	154.37M
Total Debt	2.10B
Net Cash	-1.94B
Net Cash Per Share	n/a
Equity (Book Value)	1.13B
Book Value Per Share	2.85
Working Capital	107.04M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 110.19 million and capital expenditures -56.75 million, giving a free cash flow of 53.44 million.

Operating Cash Flow	110.19M
Capital Expenditures	-56.75M
Free Cash Flow	53.44M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 61.53%, with operating and profit margins of 3.27% and 5.93%.

Gross Margin	61.53%
Operating Margin	3.27%
Pretax Margin	4.42%
Profit Margin	5.93%
EBITDA Margin	9.67%
EBIT Margin	3.27%
FCF Margin	2.01%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.01%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	5.68%
FCF Yield	1.92%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 0.93 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.93
Piotroski F-Score	6